![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CDK6 |
Gene summary for CDK6 |
![]() |
Gene information | Species | Human | Gene symbol | CDK6 | Gene ID | 1021 |
Gene name | cyclin dependent kinase 6 | |
Gene Alias | MCPH12 | |
Cytomap | 7q21.2 | |
Gene Type | protein-coding | GO ID | GO:0000082 | UniProtAcc | Q00534 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1021 | CDK6 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.50e-28 | -7.37e-01 | 0.0155 |
1021 | CDK6 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.63e-20 | -9.28e-01 | -0.1808 |
1021 | CDK6 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.01e-03 | -8.96e-01 | -0.2196 |
1021 | CDK6 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.28e-19 | -9.63e-01 | -0.1207 |
1021 | CDK6 | HTA11_83_2000001011 | Human | Colorectum | SER | 3.53e-13 | -9.09e-01 | -0.1526 |
1021 | CDK6 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.58e-24 | -6.62e-01 | -0.1464 |
1021 | CDK6 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.63e-22 | -6.97e-01 | -0.1001 |
1021 | CDK6 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.07e-03 | -4.20e-01 | -0.059 |
1021 | CDK6 | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.15e-03 | -8.07e-01 | -0.1706 |
1021 | CDK6 | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.23e-10 | -1.01e+00 | -0.2061 |
1021 | CDK6 | HTA11_5216_2000001011 | Human | Colorectum | SER | 3.85e-05 | -8.77e-01 | -0.1462 |
1021 | CDK6 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.77e-02 | -4.04e-01 | 0.096 |
1021 | CDK6 | HTA11_10711_2000001011 | Human | Colorectum | AD | 3.36e-04 | -5.34e-01 | 0.0338 |
1021 | CDK6 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.35e-12 | -5.16e-01 | 0.0674 |
1021 | CDK6 | HTA11_6818_2000001011 | Human | Colorectum | AD | 1.88e-03 | -5.51e-01 | 0.0112 |
1021 | CDK6 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.03e-02 | -3.11e-01 | 0.3859 |
1021 | CDK6 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 3.31e-15 | -1.01e+00 | 0.2585 |
1021 | CDK6 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.48e-48 | -9.77e-01 | 0.3005 |
1021 | CDK6 | F007 | Human | Colorectum | FAP | 1.84e-06 | -5.67e-01 | 0.1176 |
1021 | CDK6 | A001-C-207 | Human | Colorectum | FAP | 4.40e-11 | -6.23e-01 | 0.1278 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00025734 | Stomach | CSG | myeloid leukocyte differentiation | 21/1034 | 208/18723 | 5.63e-03 | 4.50e-02 | 21 |
GO:004477219 | Thyroid | ATC | mitotic cell cycle phase transition | 223/6293 | 424/18723 | 3.46e-16 | 2.88e-14 | 223 |
GO:003158928 | Thyroid | ATC | cell-substrate adhesion | 195/6293 | 363/18723 | 1.58e-15 | 1.17e-13 | 195 |
GO:001081029 | Thyroid | ATC | regulation of cell-substrate adhesion | 128/6293 | 221/18723 | 8.74e-14 | 4.57e-12 | 128 |
GO:000150332 | Thyroid | ATC | ossification | 206/6293 | 408/18723 | 9.23e-13 | 3.95e-11 | 206 |
GO:0007160111 | Thyroid | ATC | cell-matrix adhesion | 128/6293 | 233/18723 | 1.49e-11 | 5.41e-10 | 128 |
GO:0001952110 | Thyroid | ATC | regulation of cell-matrix adhesion | 78/6293 | 128/18723 | 2.09e-10 | 6.15e-09 | 78 |
GO:000164932 | Thyroid | ATC | osteoblast differentiation | 122/6293 | 229/18723 | 6.04e-10 | 1.60e-08 | 122 |
GO:000756829 | Thyroid | ATC | aging | 166/6293 | 339/18723 | 2.79e-09 | 6.60e-08 | 166 |
GO:0010811210 | Thyroid | ATC | positive regulation of cell-substrate adhesion | 73/6293 | 123/18723 | 4.12e-09 | 9.37e-08 | 73 |
GO:004578614 | Thyroid | ATC | negative regulation of cell cycle | 181/6293 | 385/18723 | 2.64e-08 | 5.07e-07 | 181 |
GO:0048872210 | Thyroid | ATC | homeostasis of number of cells | 135/6293 | 272/18723 | 2.92e-08 | 5.50e-07 | 135 |
GO:0009615111 | Thyroid | ATC | response to virus | 173/6293 | 367/18723 | 4.23e-08 | 7.71e-07 | 173 |
GO:000226234 | Thyroid | ATC | myeloid cell homeostasis | 84/6293 | 157/18723 | 2.12e-07 | 3.33e-06 | 84 |
GO:004484316 | Thyroid | ATC | cell cycle G1/S phase transition | 119/6293 | 241/18723 | 2.68e-07 | 4.10e-06 | 119 |
GO:004814532 | Thyroid | ATC | regulation of fibroblast proliferation | 49/6293 | 80/18723 | 3.73e-07 | 5.48e-06 | 49 |
GO:003410134 | Thyroid | ATC | erythrocyte homeostasis | 71/6293 | 129/18723 | 4.36e-07 | 6.34e-06 | 71 |
GO:000008216 | Thyroid | ATC | G1/S transition of mitotic cell cycle | 107/6293 | 214/18723 | 4.83e-07 | 6.99e-06 | 107 |
GO:000756924 | Thyroid | ATC | cell aging | 72/6293 | 132/18723 | 5.77e-07 | 8.15e-06 | 72 |
GO:004814432 | Thyroid | ATC | fibroblast proliferation | 49/6293 | 81/18723 | 6.38e-07 | 8.80e-06 | 49 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05220 | Colorectum | AD | Chronic myeloid leukemia | 31/2092 | 76/8465 | 1.41e-03 | 8.46e-03 | 5.39e-03 | 31 |
hsa05225 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
hsa05163 | Colorectum | AD | Human cytomegalovirus infection | 75/2092 | 225/8465 | 2.00e-03 | 1.10e-02 | 7.01e-03 | 75 |
hsa05160 | Colorectum | AD | Hepatitis C | 54/2092 | 157/8465 | 3.87e-03 | 1.96e-02 | 1.25e-02 | 54 |
hsa04218 | Colorectum | AD | Cellular senescence | 53/2092 | 156/8465 | 5.55e-03 | 2.48e-02 | 1.58e-02 | 53 |
hsa05212 | Colorectum | AD | Pancreatic cancer | 29/2092 | 76/8465 | 6.25e-03 | 2.68e-02 | 1.71e-02 | 29 |
hsa052201 | Colorectum | AD | Chronic myeloid leukemia | 31/2092 | 76/8465 | 1.41e-03 | 8.46e-03 | 5.39e-03 | 31 |
hsa052251 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
hsa051631 | Colorectum | AD | Human cytomegalovirus infection | 75/2092 | 225/8465 | 2.00e-03 | 1.10e-02 | 7.01e-03 | 75 |
hsa051601 | Colorectum | AD | Hepatitis C | 54/2092 | 157/8465 | 3.87e-03 | 1.96e-02 | 1.25e-02 | 54 |
hsa042181 | Colorectum | AD | Cellular senescence | 53/2092 | 156/8465 | 5.55e-03 | 2.48e-02 | 1.58e-02 | 53 |
hsa052121 | Colorectum | AD | Pancreatic cancer | 29/2092 | 76/8465 | 6.25e-03 | 2.68e-02 | 1.71e-02 | 29 |
hsa051632 | Colorectum | SER | Human cytomegalovirus infection | 57/1580 | 225/8465 | 7.40e-03 | 3.84e-02 | 2.79e-02 | 57 |
hsa051633 | Colorectum | SER | Human cytomegalovirus infection | 57/1580 | 225/8465 | 7.40e-03 | 3.84e-02 | 2.79e-02 | 57 |
hsa051634 | Colorectum | MSS | Human cytomegalovirus infection | 74/1875 | 225/8465 | 1.12e-04 | 1.01e-03 | 6.19e-04 | 74 |
hsa052252 | Colorectum | MSS | Hepatocellular carcinoma | 56/1875 | 168/8465 | 5.04e-04 | 3.45e-03 | 2.11e-03 | 56 |
hsa042182 | Colorectum | MSS | Cellular senescence | 52/1875 | 156/8465 | 7.87e-04 | 5.07e-03 | 3.11e-03 | 52 |
hsa051602 | Colorectum | MSS | Hepatitis C | 52/1875 | 157/8465 | 9.29e-04 | 5.58e-03 | 3.42e-03 | 52 |
hsa052202 | Colorectum | MSS | Chronic myeloid leukemia | 29/1875 | 76/8465 | 1.10e-03 | 6.27e-03 | 3.84e-03 | 29 |
hsa05169 | Colorectum | MSS | Epstein-Barr virus infection | 63/1875 | 202/8465 | 1.63e-03 | 8.98e-03 | 5.50e-03 | 63 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDK6 | SNV | Missense_Mutation | novel | c.262N>G | p.Thr88Ala | p.T88A | Q00534 | protein_coding | tolerated(0.49) | benign(0.015) | TCGA-AN-A0FJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CDK6 | SNV | Missense_Mutation | c.417N>A | p.His139Gln | p.H139Q | Q00534 | protein_coding | deleterious(0.02) | possibly_damaging(0.608) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
CDK6 | SNV | Missense_Mutation | c.352C>T | p.Pro118Ser | p.P118S | Q00534 | protein_coding | tolerated(0.4) | benign(0.049) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
CDK6 | SNV | Missense_Mutation | novel | c.413C>T | p.Ser138Leu | p.S138L | Q00534 | protein_coding | tolerated(0.06) | benign(0.02) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CDK6 | SNV | Missense_Mutation | c.749N>T | p.Pro250Leu | p.P250L | Q00534 | protein_coding | tolerated(0.07) | probably_damaging(0.961) | TCGA-AA-3968-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CDK6 | SNV | Missense_Mutation | rs761377867 | c.260G>A | p.Arg87Gln | p.R87Q | Q00534 | protein_coding | tolerated(0.15) | possibly_damaging(0.794) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDK6 | SNV | Missense_Mutation | c.250N>T | p.Thr84Ser | p.T84S | Q00534 | protein_coding | tolerated(0.5) | benign(0.161) | TCGA-DM-A28F-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
CDK6 | SNV | Missense_Mutation | c.431G>A | p.Arg144His | p.R144H | Q00534 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
CDK6 | SNV | Missense_Mutation | novel | c.262A>G | p.Thr88Ala | p.T88A | Q00534 | protein_coding | tolerated(0.49) | benign(0.015) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDK6 | SNV | Missense_Mutation | novel | c.248G>A | p.Cys83Tyr | p.C83Y | Q00534 | protein_coding | deleterious(0.02) | benign(0.414) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1021 | CDK6 | KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUG RESISTANCE | inhibitor | 178102290 | AT-7519 | |
1021 | CDK6 | KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUG RESISTANCE | inhibitor | CHEMBL1230607 | PHA-793887 | |
1021 | CDK6 | KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUG RESISTANCE | inhibitor | 387065614 | ||
1021 | CDK6 | KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUG RESISTANCE | inhibitor | CHEMBL428690 | ALVOCIDIB | |
1021 | CDK6 | KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUG RESISTANCE | inhibitor | CHEMBL3545110 | RIBOCICLIB | |
1021 | CDK6 | KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUG RESISTANCE | PMID25726713-Compound-48 | |||
1021 | CDK6 | KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUG RESISTANCE | CS1229 | |||
1021 | CDK6 | KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUG RESISTANCE | inhibitor | 387065613 | ||
1021 | CDK6 | KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUG RESISTANCE | inhibitor | CHEMBL445813 | AT-7519 | |
1021 | CDK6 | KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUG RESISTANCE | inhibitor | 363894217 | VORUCICLIB |
Page: 1 2 3 4 5 6 |